- Briefing docs are out for next week's Northera (CHTP) Ad Com.
- FDA staff list five arguments in favor of approval and seven against approval.
- "The primary reason not to recommend approval is the lack of sufficient evidence of efficacy," the documents say.
- Full documents
- CHTP -21% premarket
on your portfolio: